7 completed, 3 unknown. 7 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Unknown 3 |
| Phase 1 | 3 | Completed 3 |
Follow 3BNC117 antibody: new trials by email Literature Review of 3BNC117 antibody trials Research Report on 3BNC117 antibody
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection Albuvirtide, 3BNC117 Antibody - HIV/AIDS | Phase 2 | Unknown | Frontier Biotechnologies Inc. | 20 | 2021-11-30 | 2021-09-29 |
| Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection Albuvirtide, 3BNC117 - HIV/AIDS | Phase 2 | Unknown | Frontier Biotechnologies Inc. | 24 | 2021-05-01 | 2021-03-26 |
| Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects Albuvirtide, 3BNC117, Baseline ART - HIV-1-infection | Phase 2 | Unknown | Frontier Biotechnologies Inc. | 80 | 2018-12-17 | 2021-09-29 |
| 3BNC117 and 10-1074 in ART-treated Individuals 3BNC117, 10-1074, Analytical treatment interruption - Human Immunodeficiency Virus | Phase 1 | Completed | Rockefeller University | 26 | 2018-06-05 | 2025-10-01 |
| Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART Romidepsin, 3BNC117, Antiretrovirals - Hiv | Phase 2 | Completed | Aarhus University Hospital | 60 | 2017-01-20 | 2025-04-18 |
| Romidepsin Plus 3BNC117 Phase 2a Study 3BNC117, Romidepsin - Human Immunodeficiency Virus (HIV) | Phase 2 | Completed | Rockefeller University | 48 | 2017-01-06 | 2022-07-14 |
| 3BNC117 and 10-1074 in HIV Uninfected Adults 3BNC117, 10-1074, Placebo - Human Immunodeficiency Virus | Phase 1 | Completed | Rockefeller University | 24 | 2016-06-23 | 2018-04-17 |
| 3BNC117 and 10-1074 in HIV-infected Individuals 3BNC117, 10-1074, Analytical treatment interruption - Human Immunodeficiency Virus (HIV) | Phase 1 | Completed | Rockefeller University | 34 | 2016-06-01 | 2018-08-21 |
| A Study of the Safety and Antiretroviral Activity of 3BNC117 3BNC117, Antiretroviral Treatment Interruption - HIV-1 Infection | Phase 2 | Completed | Rockefeller University | 17 | 2015-10-01 | 2021-06-16 |
| 3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption 3BNC117, ART Interruption - HIV-1 Infection | Phase 2 | Completed | Rockefeller University | 16 | 2015-03-11 | 2020-07-23 |
Acquired Immunodeficiency Syndrome (7)
Rockefeller University (6) · Frontier Biotechnologies Inc. (3) · Aarhus University Hospital (1)
United States (8) · Denmark (2) · Germany (2) · China (1) · United Kingdom (1)
Marina Caskey, MD (5) · Cheng Yao (1) · Cheng Yao, M.D. (1) · Yehuda Cohen, MD (1)
PMID 32838558, PMID 31393868, PMID 35544074, PMID 36253609, PMID 41896772
2015 (1), U01AI118536 (1)